Mutations in the von Hippel-Lindau (VHL) gene are frequently detected in human sporadic renal cell carcinoma (RCC). We analysed 102 Swedish RCCs for VHL mutations by PCR ± SSCP and sequencing. In 47 patients (46.1%), 70 dierent mutations were found, and most of them represented novel variations of the VHL gene. Mutations in the VHL gene were found in 54% of clear cell renal cell carcinomas (CCRCC) and in 18% of chromophilic cancers but in no chromophobe cancers or oncocytomas (P=0.016). Three novel hotspot or founder mutations were detected in our study: four CCRCCs carried a missense mutation (glutamic acid to lysine) at codon 160 which is critical in the stabilization of the H1 helix of the a domain and the a-b domain interface in the VHL protein. Five CCRCCs and one chromophilic RCC harbored a 15-nucleotide in-frame deletion (codons 41 ± 45) at a duplex tandem repeat sequence site. Moreover, this deletion was in linkage disequilibrium with a C?T transition in the promoter region. The frequency of linkage was 17 times more common than chance. Five patients with this linked mutation resided in the same hospital district and at least three of them showed the two sequence variants in the tumor-adjacent tissue. In 5/ 6 patients the wild-type allele was lost in the tumor samples, suggesting a causal role for the mutations in RCC. These linked mutations might be novel polymorphisms maintained in a relative isolated population. Multiple mutations in VHL were found in 17 tumors out of 47 tumors with the VHL mutation. A higher multiple mutation detected rate (33%) was observed in grade 3 CCRCCs than those in grade 1 (22%) and grade 2 (9%) (P=0.04). This is evidence on the association between VHL mutation and extent of nuclear atypia. Oncogene (2001) 20, 5393 ± 5400.
Introduction
Renal cell carcinoma (RCC) is the most common malignancy of human kidney and accounts for approximately 2% of adult malignancies. It is estimated that the world-wide incidence of renal cell carcinoma has increased at an annual rate of approximately 2%, especially in North America and northern Europe (McLaughlin and Lipworth, 2000) . Occupational and life-style exposures to a variety of carcinogens, such as trichloroethene, asbestos, cadmium, dyes, some petroleum products, insecticides, drugs, herbicides and tobacco, have been associated with sporadic RCC (McLaughlin and Lipworth, 2000; McLaughlin et al., 1995; McCredie et al., 1995; Mandel et al., 1995) .
The von Hippel-Lindau (VHL) gene alterations are responsible for a rare hereditary cancer syndrome (von Hippel-Lindau disease), including inherited RCC (Latif et al., 1993) . Molecular analyses of the VHL gene have indicated that VHL germline mutations are linked to hereditary clear cell renal cell carcinoma (CCRCC) Yoshida et al., 2000) . In the last few years, evidence has accumulated on the association of somatic VHL mutations with sporadic RCC (Prowse et al., 1997; Zhuang et al., 1996; Beroud et al., 1998; Yang et al., 1999; Brauch et al., 2000) . A VHL gene mutation frequency of 33 ± 57% and loss of heterozygosity (LOH) frequency at the VHL locus of up to 98% have been reported , speci®cally in sporadic CCRCC, which accounts for some 80% of adult sporadic RCC. Biochemical studies have revealed that the VHL protein (pVHL) forms a ternary complex with the elongin C and elongin B proteins, which might be involved in many important cellular functions, such as targeted protein degradation, control of angiogenesis, and control of cell cycle (Pause et al., 1997; Siemeister et al., 1996; Gorospe et al., 1999; Schoenfeld et al., 2000a,b) . Molecular analyses of mutations have shown that half of the tumorigenic mutations map to the pVHL domain interacting with elongin C (Stebbins et al., 1999) .
Analysis of mutations in tumor suppressor genes has been used to predict clinical behavior and prognosis of cancers, and to provide clues about cancer etiology. Successful examples of the latter are p53 mutation analyses in which speci®c mutation patterns in skin, hepatocellular and lung carcinoma have been associated with predominant environmental risk factors, i.e. UV light, a¯atoxin B and tobacco smoking, respectively (Greenblatt et al., 1994) . Recently, VHL alterations have been associated with exposure to trichloroethylene (Brauch et al., 1999; Bruning et al., 1997; Schraml et al., 1999) . RCC from trichloroethylene-exposed patients showed up to 100% somatic VHL mutations. The mutations were frequently multiple, which associated with the severity of exposure to trichloroethylene. VHL mutations were also found in rat renal epithelial tumors induced by N-nitrosodimethylamine, existing in e.g., cigarette smoke (Shiao et al., 1998) . These ®ndings suggested that carcinogens constituted a genotoxic eect on the VHL gene, resulting in loss-of-function variations of this tumor suppressor gene. A public database on VHL mutations has been established with over 700 mutations currently (Universal VHL-Mutation Database, http://www.umd.-necker.fr). The accumulated data show a nonrandom distribution of somatic VHL mutations, including putative hotspot mutations, with possible etiological links.
The Nordic countries, and particularly Sweden, have a relatively high incidence of RCC, and a case-control study has been carried out to search for etiological clues to this McCredie et al., 1995; McLaughlin et al., 1995; McLaughlin and Lipworth, 2000) . We have collected archival tumor material from this case-control study and analysed here 102 microdissected tumor samples for VHL mutations. A pilot study on 30 patients has been published (Yang et al., 1999) .
Results

VHL mutation frequency associated with tumor type of RCCs and tumor grade of CCRCCs
One hundred and two RCC tumor samples were analysed and a total of 82 sequence variations were detected in 47 out of 102 RCCs (46.1%). They shared 70 dierent mutation entities. Most of them represented novel mutations when we searched the Universal VHL-Mutation Database (http://www.umd. necker.fr) currently containing more than 700 reported mutations (Beroud et al., 1998) . VHL mutation frequencies varied in dierent tumor types and tumor grades (Table 1) . Clear cell renal cell carcinoma presented a higher mutation rate (54%) than other tumor types (chromophilic 18%, chromophobe 0%, and oncocytoma 0%). The dierence in mutation rates between the histological types was statistically signi®cant (w 2 testing, P=0.016). Among 81 CCRCCs, mutation frequencies in grades 1 to 4 tumors were 33, 54, 64 and 50%, respectively, showed an increasing trend but failing to reach statistical signi®cance. Multiple mutations occurred more frequently in grade 3 CCRCC (33%) than those in grade 1 (22%) and 2 (9%) (multiple mutation rate between grades 2 and 3, w 2 testing, P=0.04).
Characteristics and distribution of VHL mutations
All detected mutations were listed in Table 2 . Their exonic locations were shown in Figure 1 . Data in Table  2 It is noteworthy that even though some tumors harbored two missense mutations (13FT, 3GT, 11GT), no sample contained more than one stop mutation. A rarely reported mutation, T at nucleotide 621 replaced by GA, was found in a CCRCC (2O È T).
Hotspot/founder mutations
In our series, three mutations were found more than once. A C?T transition at nucleotide 165 in the promoter region, was found in ®ve tumors (13FT, 1VT, 3VT, 6VT, 9VT). The second hotspot, a G?A transition at nucleotide 691, resulting in a change of VHL mutations in renal cell carcinoma X Ma et al codon 160 from glutamic acid to lysine, was detected in four CCRCCs (11ET, 9FT, 13GT, 1GT). As the third hotspot, ®ve CCRCCs (13FT, 1VT, 3VT, 6VT, 8VT) and one chromophilic RCC (9VT) showed a 15-nucleotide in-frame deletion (AAGAGTCCGGCC-CGG or AGAGTCCGGCCGGA) at nucleotide 335 or 336 (codon 41 ± 45). The 15-nucleotide deletion occurred at a duplex tandem repeat sequence which is believed to be a fragile site for deletion. Five patients with this deletion resided in the same hospital district (VaÈ steraÊ s). Moreover, the deletion was also detected in the microdissected surrounding normal tissue from four tumors (13FT, 1VT, 3VT, 8VT but not in 6VT), but normal tissue sample of 9VT failed to be analysed because of poor DNA quality. We did not ®nd this mutation when we screened another 40 healthy controls who resided in one of the eight hospital districts (Sundsvall). Unfortunately, it is not possible to determine if the deletion was an inherited polymorphism or a sporadic mutation, because no other normal tissue (e.g. blood) was available from these patients or their biological relatives (parents and siblings). None of patients with these recurrent mutations showed an unusual age of onset for RCC (Table 2) . LOH in tumor samples containing the 15-nucleotide deletion was analysed using size determination of the PCR products in a DNA sequencer (Figure 2 ). The tumor sample from patient 8VT lacks completely the wild-type allele indicating that an LOH had taken place. The analysis could be carried out on ®ve tumor and normal samples (normal tissue of 9VT did not amplify) and all but one showed a loss of the wild-type allele. Analysis of the SSCP and sequencing data con®rmed the ®ndings and also indicated that even in sample 9VT loss of the wild-type allele had taken place. Thus an LOH event was seen in 5/6 tumors and in all cases the wild-type allele was lost.
Linkage disequilibrium
The two hotspot mutations, the 15-nucleotide in-frame deletion (AAGAGTCCGGCCCGG or AGAGTCCG-GCCGGA) at nucleotide 335/336 and the C?T transition at nucleotide 165 in the promoter region were linked in ®ve tumors (13FT, 1VT, 3VT, 6VT, 9VT), i.e., in all but one case where both mutations were found, and in the surrounding microscopically normal tissues of three tumors (13FT, 1VT, 3VT; not in 6VT, 9VT did not amplify). They are in linkage disequilibrium, exceeding chance 17 times (i.e., 5/102 divided by 566/102 2 ; 95% con®dence intervals 5.1 ± 55.2).
Discussion
The contribution of VHL mutation to onset of human RCC has been observed in hereditary and sporadic RCCs from previous studies Brauch et al., 2000; Meyer et al., 2000) . Our data showed that VHL mutations mainly occurred in clear cell renal cell carcinoma, which is consistent with other reports (Brauch et al., 2000; Gnarra et al., 1994; Prowse et al., 1997) . Tumor-type speci®city of VHL mutation suggests that dierent carcinogeneic mechanisms underlie dierent tumor types of RCC, and might determine dierent biological behaviors of tumors, e.g. invasiveness and metastasis. A recent study (Brauch et al., 2000) has suggested that the VHL mutation rate was signi®cantly associated with advanced tumor stage (pT 3 ) of CCRCC. Our data indicated multiple mutations occurred more frequently in grade 3 than those in grade 1 and 2, which is the ®rst evidence for the association between heterogeneity of VHL mutations and extent of nuclear atypia in CCRCC.
Association between VHL mutations and loss of pVHL function has been established (Stebbins et al., 1999) . The VHL protein has two domains: a smaller ahelical domain (a domain) and a b domain rich in b sheet. A large portion of the a domain surface and a small portion of the b domain interact with elongin C. Two linkers and a polar interface hold the a and b domains together. About one half of the tumorigenic mutations harbored in the a domain and its residues that contact elongin C; the remaining mutations mapped to the b domain. It has been suggested that the tumor suppressor function of pVHL requires an intact binding site of a and b domains (Stebbins et al., 1999) . A G?A transition at nucleotide 691, a novel hotspot mutation in our study, resulted in a missense mutation from glutamic acid to lysine at codon 160. Glu 160 interacts with Arg 167 , a reported hotspot mutation in a previous study (Beroud et al., 1998) , by hydrogen bonding, and exerts a stabilizing role for the H1 helix at the a domain and the a-b domain interface. If either Glu 160 or Arg 167 were replaced, the H1 helix could become unstable, resulting in a failure of pVHL to bind elongin C.
The other hotspot/founder mutation, the 15-nucleotide in-frame deletion at the duplex tandem repeat sequence at nucleotide 335/336, covering residues 41 to 45, was detected in tumors and in 4 ± 6 surrounding, microscopically normal tissue. Tandem repeats are sensitive sites for deletions or insertions, apparently because of DNA polymerase slippage. Studies of the pVHL structure have revealed that the deleted short sequence (residue 41 ± 45) is not involved in the functions of the a domain (residues 63 ± 154) nor of the b domain (residues 193 ± 204) of pVHL (Stebbins et al., 1999) . Interestingly, ®ve out of six patients with this mutation in RCC came from the same area, suggesting that the mutation/polymorphism may not be an independent event. In other studies (Brauch et al., 1999 (Brauch et al., , 2000 , reporting somatic VHL mutation hotspots, geographical and epidemiological dierences in the occurrence of RCCs, suggested completely independent causation. The presence of the 15-nucleotide deletion in tumor-adjacent tissue raises the possibility that it was a germline alteration and possibly related to the VHL disease. Yet, the available information failed to incriminate VHL disease: renal Oncogene VHL mutations in renal cell carcinoma X Ma et al tumors were not of early onset and none of the tumors reported in the ®rst-degree relatives matched those belonging to the syndrome. Such data cannot exclude a low-penetrance variant of the disease. Whether the deletion is causally related to renal cancer cannot be ®rmly established. However, LOH in 5/6 tumors and the retention of the allele with deletion is suggestive of a causative role. Furthermore the deletion was the only alteration causing a structural change in pVHL in 3/6 tumors.
The third hotspot, the C?T transition at nucleotide 165 in the promoter region was found in ®ve tumors. In three tumors the variant was also found in the tumor-adjacent tissue. All of them also showed the 15-nucleotide deletion. The linkage disequilibrium between these two mutations, exceeding chance 17 times, is probably due to an inherited haplotype and suggests a common ancestral origin. Accordingly, all but one of these patients resided in the same hospital district. Observations on rare hereditary diseases in relatively b yes means mutation occurred at a CpG site Figure 1 The X-axis indicates the number of the residue aected by mutations, their exonic location and residues forming a and b domains of pVHL. The Y-axis indicates the number of renal cell carcinomas carrying mutations at designated residues isolated small populations have suggested that a variant allele can be introduced by a founder (founder eect) or it can be a new mutation. The fact that the two variants are in a linkage disequilibrium imply that the variants were either brought about at a single event or that the population has experienced a relatively recent bottle neck. Whether the C?T transition at nucleotide 165 has an etiological role in renal cancer or whether it is an innocuous polymorphism cannot be answered. The present patient material comes from an epidemiological study and a lot of exposure information has been collected on the patients . We are in the process of analysing this systematically in terms of the found mutations. However, so far no exposures have been found that could explain mutations or any of the speci®c mutation types. The only occupational exposure that associated with VHL mutations, and particularly with multiple mutations, was exposure to welding fumes (relative risk 4.9 for multiple mutations, P=0.04). The 15 nucleotide deletions were increased in exposure to asbestos but the increase was not statistically signi®cant (relative risk 4.1, P=0.2).
The rare mutation T?GA suggests a misincorporation event involving an insertion. Among the other , the alteration aected the binding interface of pVHL to elongin C (Stebbins et al., 1999) . A large proportion of the missense and frameshift mutations detected in our study directly or indirectly aect the functional sites of pVHL, which are mainly located between residue 63 and 204 (Meyer et al., 2000; Stebbins et al., 1999) (Figure 1) We used paran-embedded tumor material in our study and mutational artifacts are more common in DNA from such material than in DNA from un®xed tissue. However, we carried out analyses of mutated samples at least twice from the original DNA to con®rm the ®ndings. Moreover, the 15 nucleotide deletion was independently demonstrated in size separating gels ( Figure 2 ). As a third argument, it would be very unlikely that two tightly linked polymorphisms some 140 nucleotides apart would coexist as artifacts in repeated analysis.
Frequent multiple mutations in the VHL gene were detected here and in previous studies (Brauch et al., 1999 (Brauch et al., , 2000 . An association was suggested between the number of multiple mutations in the VHL gene and the extent of exposure to trichloroethylene (Brauch et al., 1999) . In the present study, multiple mutations always included at least one missense or silent mutation, suggesting that they were not as critical for tumorigenesis as were truncation mutations. Moreover, some missense types of multiple mutations did not aect the functional a and b domains of the protein. In the present study we did not determine LOH around the VHL locus. In a previous study, most tumors with multiple VHL mutations also showed LOH, suggesting that the allelic loss was the mechanism of transformation (Brauch et al., 2000) . Identical mutations existing in one tumor may suggest origin by the same type of a mutagenic event, perhaps acting during a long period of time. GC?AT transitions accounted for 54% of VHL mutations in our study. One half of the multiple mutations involved CpG sites, in line with the methylated C being a hypermutable site (Denissenko et al., 1997) . The detected mutations in our data and in the Universal VHL-Mutation Database (http:// www.umd.necker.fr) dominantly clustered in exon 1 and exon 3 which are rich in the CpG sites. Nonenzymatic O 6 -alkylation of deoxyguanosine and mispairing of O 6 -alkyl-guanine with thymine is a known mechanism underlying G?A mutations (Lindahl, 1993; Denissenko et al., 1997; Day et al., 1987) .
In summary, the present work on 102 RCC patients, 47 of whom had 82 mutations/sequence variants in VHL revealed many new ®ndings. Multiple mutations associated with tumor grade. Three recurrent sequence variants were found and two of them were linked, suggesting that they presented a germline haplotype. There was no evidence that the patients had a VHL disease; however, the variants appeared to carry a risk of RCC because in some patients no other VHL mutations were found. Missense GC?AT mutations were the most common mutation. Tumors with multiple mutations included at least one missense or silent mutation, while frameshifts predominated in tumors with a single lesion.
Material and methods
Samples
The patients were identi®ed from a previous case-control study on RCC Archival paran embedded samples of tumor and surrounding microscopically normal tissue were requested from pathology departments in the study areas. The slides of tumors were reviewed again by a pathologist (Lars Egevad). The tumors were classi®ed according to histological type using the system introduced by Thoenes et al. (1990a,b) and graded from 1 to 4 according to nuclear atypia. A representative slide with a cancer area was selected from each case. Cancer was outlined with Indian ink on the slide. A 50 mm section was cut from the paran block and any non-neoplastic tissue was trimmed away from the section obtained.
DNA extraction and mutation detection
Genomic DNA samples were isolated from the paran embedded sections by the method described before (Yang et al., 1999) . VHL gene was ampli®ed by ®ve pairs of PCR primers (104/105, F5/R8, 7/22-1, 21/24, and E3F/E3R) (Gnarra et al., 1994a; Crossey et al., 1994; Sekido et al., 1994) . PCR products were labeled by 32 P-dCTP during the ampli®cation process. Then PCR ampli®ed fragment was denatured by adding 5 ml of denaturing buer (95% formamide, 10 mM NaOH, 0.05% bromophenol blue and 0.05% xylene cynanol FF) to 1 ml of PCR solution, heating at 958C for 1 min and cooling on ice. Three conditions of electrophoresis were used for SSCP analysis: 5% polyacrylamide gel with 5% glycerol, running with 0.56TBE buer at room temperature; 5% polyacrylamide gel, running with 0.56TBE buer at 48C; and 0.56MDE (FMC BioProducts) gel, running with 0.66TBE buer at room temperature. A ®lm was exposed to the dried SSCP gel. The SSCP results were scrutinized by two persons. PCR and SSCP were repeated for the samples with positive ®ndings, starting from the original DNA. The shift bands on SSCP gel were sequenced by PCR based sequencing on ABI 377.
For size determination of PCR products, samples were ampli®ed with a¯uorescent primer and the products were analysed in an ALF Express sequencer together with size markers.
